Embora a utilização do corticóide oral não seja indicada no tratamento de manutenção na doença pulmonar obstrutiva crônica, identificamos em nosso ambulatório, um grupo de pacientes que fazem uso desta medicação de forma continuada e, nos quais, todas as tentativas anteriores de retirada da medicação, havia resultado em exacerbação dos sintomas. O objetivo deste estudo foi o de analisar os fenômenos inflamatórios associados à tentativa de redução progressiva do corticóide oral nesses doentes. Avaliamos o escarro induzido de 14 pacientes usuários crônicos de corticóide. Após a avaliação basal, realizada enquanto os pacientes faziam uso de sua dose habitual da medicação (V0), procedemos ao aumento da prednisona a 40 mg por dia, por duas semanas (V1). A seguir, reduzimos progressivamente a dose até que ocorresse uma exacerbação (EXAC), quando a dose de 40 mg de prednisona foi re-introduzida por duas semanas (APÓS). Comparamos os resultados deste grupo aos de um grupo de pacientes portadores de DPOC não-usuários de corticóide oral. Esses pacientes foram avaliados na condição basal (V0), quando exacerbaram (EXAC) e após o tratamento com 40 mg de prednisona, por duas semanas (APÓS). As variáveis analisadas no escarro foram: % de neutrófilos, % de eosinófilos, % de macrófagos, número total de células, interleucinas 4, 6 e 8. Constatamos que o grupo corticóide apresentou um aumento significativo na porcentagem de eosinófilos na exacerbação em relação a V0, e uma redução significativa em APÓS, em relação a EXAC. Isto não ocorreu no grupo não-corticóide. Ao compararmos os dois grupos, observamos que a concentração das interleucinas 4, 6 e 8, foi significativamente mais alta no grupo corticóide em V0 e na exacerbação em relação ao grupo não-corticóide. Quando analisamos o comportamento das interleucinas nas avaliações seqüenciais, dentro de cada grupo, observamos que a interleucina 4 tendeu à elevação na exacerbação, no grupo corticóide, sem atingir, entretanto, significância estatística. As interleucinas 6 e 8 aumentaram significativamente no grupo corticóide na visita APÓS. Concluímos que a retirada progressiva de corticóide oral induz a exacerbação em pacientes com DPOC corticóide-dependentes com um processo inflamatório eosinofílico, que tende à reversão após o aumento da dose do corticóide / Although in chronic obstructive lung disease the use of oral corticoid is not indicated in the maintenance treatment, we identified a group of patients that make use of this medication continuously. The objective of this study was to analyze the inflammatory phenomena associated to the attempt of progressive reduction of oral corticoids in these patients. We evaluated induced sputum of 14 patients on long-term use of oral corticoids. After the basal evaluation, accomplished while the patients made use of their habitual dose of the medication (V0), we increased the dose of prednisone to 40 mg daily for two weeks (V1). To proceed we reduced the dose progressively until an exacerbation occurred (EXAC), when the dose of prednisone 40 mg daily was reintroduced for two weeks (AFTER). We compared the results to a group of patients with COPD not on use of oral corticoids, that were appraised in the basal condition (V0), when they exacerbated (EXAC) and after the treatment with prednisone 40 mg daily for two weeks (AFTER). The variables analyzed in the sputum were:, % of neutrophils, % of eosinophils, % of macrophages, total number of cells, interleukins 4, 6 and 8. We verified that the corticoid group presented a significant increase in the percentage of eosinophils at the exacerbation in relation to V0, and a significant reduction in AFTER in relation to EXAC. This didn\'t happen in the non corticoid group. When we compared the two groups we observed that the concentration of the interleukins was significantly higher in corticoid group in V0 and at the exacerbation in relation to the non corticoid group. When we analyzed the behavior of the interleukins along the evaluations in each group we observed that interleukin 4 tended to an elevation at the exacerbation in the corticoid group, without reaching statistical significance. Interleukins 6 and 8 increased significantly in the corticoid group in the visit AFTER. We concluded that the progressive reduction of oral corticoid induces exacerbation in patients with COPD on long-term use of prednisone with an eosinophilic inflammatory process that tends to reverse after the increase of the dose of the corticoid

Objetivos: Avaliar a utilidade dos mediadores pró-inflamatórios (TNF-alfa, IL-1 beta e IL-6), dos mediadores antiinflamatórios (IL-10 e IL-1Ra) e da Proteína C reativa (PCR) para o diagnóstico na sepse neonatal; verificar se os valores séricos isolados ou a relação entre IL-6 e IL-1Ra têm valor preditivo de gravidade, na evolução clínica da doença; determinar se a homeostase entre os mediadores pró-inflamatórios e antiinflamatórios e a PCR definem o prognóstico da doença. Casuística e métodos: Foram incluídos no estudo 31 recém-nascidos (RN) internados na UCINE ou no Hospital Universitário com diagnóstico de sepse, baseado em critérios clínicos e laboratoriais. Os RN com diagnóstico de sepse foram subdivididos em dois grupos de acordo com a evolução clínica: grupo sepse: os que tiveram boa evolução e grupo sepse grave, os que tiveram evolução complicada por choque séptico e/ou CIVD e/ou FMOS e/ou óbito. Além dos exames de rotina para sepse, forma mensurados nos dias 0, 3 e 7 de evolução a partir do diagnóstico, os níveis séricos de TNF-alfa, IL-1 beta, IL-6, IL-10 e IL-1Ra. Resultados: Na análise evolutiva geral, todos os mediadores inflamatórios apresentaram mensuração elevada no dia do diagnóstico (dia 0), com decréscimo dos valores no decorrer do tempo. Entre os mediadores pró-inflamatórios, a TNF-alfa, a IL-6 e a IL-1 beta se mostraram adequados para o diagnóstico, no entanto para o seguimento, a melhor foi a IL-6. Entre os mediadores antiinflamatórios a IL-10 seguiu os padrões dos mediadores próinflamatórios acompanhando a resolução do processo séptico, enquanto a IL-1Ra apresentou decréscimos até o 3º dia e permaneceu estável até o 7º dia caracterizando a perpetuação da ação antiinflamatória desta citocina. Quanto às relações entre mediadores pró-inflamatórios e antiinflamatórios (relação IL-6/IL-1Ra e IL-6/(IL-6 + IL-1Ra) observamos que a IL-6/IL-1Ra apresentou relação com a evolução do processo séptico, mostrando inicialmente predomínio da ação próinflamatória no dia 0 e antiinflamatória no dia 7. A PCR acompanhou de forma muito semelhante as curvas da TNF-alfa, L-6 e IL-10. Quando se subdividiu a casuística em grupos, sepse e sepse grave, observamos que os RN com sepse com boa evolução apresentaram níveis séricos médios de TNF-alfa, IL-1 beta e IL-10 próximos aos níveis mínimos detectáveis e estas citocinas nos RN com sepse grave. / Objectives - To evaluate the utility of the pro-inflammatory mediators (TNF-alfa, IL1-beta, and IL-6), the anti-inflammatory mediators (IL-10 and IL-1Ra) and C-Reactive Protein (CRP) for the diagnosis of neonatal sepsis; to verify whether the isolated seric values or the relation between IL-6 and IL-1Ra have predictive values for severity regarding the clinical outcome, and to ascertain if the homeostasis between the pro-inflammatory and anti-inflammatory mediators and CPR can define the prognosis of the disease. Patients and Methods - The study included 31 newborns (NB) admitted to the UCINE (External Neonatal Unit) or to Hospital Universitário (São Paulo University Hospital) with diagnosis of sepsis based upon clinical and laboratorial parameters. The NB with diagnosis of sepsis were further subdivided into 2 groups according to the clinical outcome: sepsis group: containing those NB who evolved to a positive outcome, and severe sepsis group, in turn composed of the NB with unsatisfactory outcomes due to complications caused by septic shock and/or DIVC and/or FMOS and/or death. On days 0, 3, and 7 following diagnosis the seric levels of TNF-alfa, IL-1 beta, IL-6, IL-10, and IL-1Ra were measured in addition to the routine sepsis workup. Results - The general follow-up analysis revealed that all the inflammatory mediators presented elevated levels at diagnosis (day 0) with a decrease of these values over time. Regarding the pro-inflammatory mediators, TNF-alfa, IL-6 and IL-1 beta were satisfactory for diagnosis, whereas IL-6 was more accurate for follow-up. In relation to the anti-inflammatory mediators, IL-10 revealed the same pattern of the pro-inflammatory mediators following the septic process resolution, whereas IL-1Ra gradually decreased until the 3rd day but hence remained stable until the 7th day, thus characterizing the continuity of the anti-inflammatory action of this cytokine. Concerning the inter-relation between the pro and anti-inflammatory mediators (IL-6/IL-1Ra relation and IL-6/(IL6+IL-1Ra)) we observed that the IL-6/IL-1Ra correlated with the septic process evolution with predominance of the proinflammatory action on day 0 and of the anti-inflammatory action on day 7. The CRP levels, we observed that in the sepsis group with satisfactory outcome on day 0 the seric values were higher than in the severe sepsis group, although on days 3 and 7 these values decreased more substantially, while in the sepsis group they increased on day 3 followed by a gradual decrease until day 7. Conclusions - The analyzed mediators were effective in the diagnosis of neonatal sepsis and also predictive of the degree of severity, mainly with regards to cytokines IL-6 and IL-1Ra. The homeostatic equilibrium/disequilibrium was correlated to the type of disease outcome: sepsis with no complications versus severe sepsis.

O treinamento aeróbico (TA) traz benefícios para os asmáticos, porém os mecanismos antiinflamatórios não são conhecidos. Estudos experimentais de asma têm mostrado que o TA reduz a inflamação pulmonar alérgica crônica (IPAC) e a reposta Th2, no entanto, nenhum estudo explicou quando os efeitos protetores são iniciados e qual é a principal via anti-inflamatória desencadeada. Objetivo: Avaliar o efeito do TA ao longo do tempo em um modelo murino de asma visando identificar quando são iniciados os efeitos anti-inflamatórios e a reversão do remodelamento brônquico (RB). Métodos: BALB/c (160 animais) foram divididos em 4 grupos: Controle (CT): não induzidos à IPAC e não treinados; Treinamento Aeróbico (TA): não induzidos à IPAC e treinados; OVA: induzidos à IPAC e não treinados; OVA+TA: induzidos à IPAC e treinados. Em seguida foram criados outros subgrupos 1, 3, 7, 15 e 30 dias de TA, ou seja, cada grupo foi repetidos 5 vezes para investigação do efeito do TA ao longo do tempo. Os grupos OVA foram sensibilizados com i.p. (OVA+HidroxAlum), após foram induzidos à IPAC com aerosol de OVA (1-3%) iniciado no dia 21 (3 x semana; 30 min./sessão). A adaptação ao TA foi realizada entre os dias 21 a 23, no dia 25 foi realizado o teste físico, no dia 28 o TA foi iniciado (50% intensidade, frequência 5 x, por 4 semanas). Vinte quatro horas da ultima sessão de TA (1, 3, 7, 15 e 30 dias) os animas foram anestesiados, eutanizados e coletados o lavado broncoalveolar (LBA) (contagem celular total e diferencial), sangue para quantificação das imunoglobulinas (IgE e IgG1) por técnica de reação de anafilaxia cutânea passiva (PCA), o tecido pulmonar para avaliação dos mediadores: IL-4, IL-5, eotaxina, RANTES, ICAM-1, VCAM-1, TGF-b, VEGF, Osteopontina (OPN), NF-kB, FOXP3, receptor de glicocorticóide (RG) e anti-inflamatórias IL-10 e IL-1ra (imunohistoquímica e quantificação por morfometria) e foi coletado também o músculo quadríceps para avaliação da produção das miocinas (IL-10, IL-1ra e IL-6) (imunohistoquímica e quantificado por análise de imagem). O RB (músculo liso, epitélio, deposições das fibras de colágeno e elástica e produção de muco) também foi avaliado por análise de imagem. Resultados: Não foi observada produção das miocinas (p>0,05). Os níveis de IgE, IgG1, migração celular, produção dos mediadores inflamatórios e o RB foram aumentados nos grupos OVA (p<0,05), que ainda mostraram redução da produção do RG (p<0,05). O TA aumentou o RG no músculo liso das vias aéreas, as produções de IL-10 e IL- 1ra aumentaram a partir do 7º dia por células peribrônquicas, ao mesmo tempo que foram reduzidos o NF-kB, IL-4, IL-5, eotaxina, RANTES, ICAM-1, VCAM-1, VEGF, eosinófilos no LBA e foram revertidos o espessamento do músculo liso, do epitélio e as deposições de fibras de colágeno (p<0,05). Curiosamente, a diminuição de TFG-b ocorreu após o 3º dia, enquanto OPN, elástica e muco ocorreram após 15 dias de TA, enquanto IgE, IgG1 e neutrófilos apenas foram reduzidas ao final de 30 dias (p<0,05). Conclusão: A partir do 3º dia do TA foi iniciado o mecanismo anti-inflamatório pelo aumento do RG no músculo liso das vias aéreas, seguido pelo aumento de IL-10 e IL-1ra e pela redução de NF-kB a partir do 7º dia do TA, efeitos que reverteram a inflamação alérgica crônica e o RB / The aerobic training (AT) promotes benefits for asthmatics, but the anti-inflammatory mechanisms are not known. Experimental studies of asthma have shown that AT reduces the pulmonary allergic chronic inflammation (PACI) and response Th2, however no study has ever explained when the protective effects are initiated and which is the main anti-inflammatory pathway triggered. Aim: To evaluate the effect of AT over time in a murine model of asthma to identify when the anti-inflammatory effects is started and reverse bronchial remodeling (BR). Methods: BALB/c (160 mice) were divided into 4 groups: Control (CT): not induced to PACI and untrained; Aerobic Training (TA): not induced to PACI and trained; OVA: induced to PACI and untrained; OVA + TA: induced to PACI and trained. After that were created others subgroups 1, 3, 7, 15 and 30 days AT, that is, each group was repeated 5 times to investigate the effect of AT over time. The OVA groups were sensitized with i.p. OVA (OVA+AlumHidrox), and then the mice were induced after the PACI with aerosol of OVA (1-3%) started on the 21st day (3 x week, 30 min./Session). Adaptation to TA was held between 21-23, on the 25th day the physical test was performed, and on day 28 AT was begun (50% intensity, frequency x 5 for 4 weeks). Twenty four hours of the after last session of AT (1, 3, 7, 15 and 30 days) the mice were anesthetized, euthanized and the bronchoalveolar lavage fluid was collected (BALF) (Total and differential cell count) and blood was used to quantify immunoglobulins (IgE and IgG1) by passive cutaneous anaphylaxis reaction (PCA) technique, the pulmonary tissue was removed and used to evaluate the mediators IL-4, IL-5, eotaxin, RANTES, ICAM-1, VCAM-1, TGF-b, VEGF, osteopontin (OPN), NF-kB, FOXP3, glucocorticoid receptor (GR), and antiinflammatory IL-10 and IL-1ra (immunohistochemistry and quantified by morphometry), was also the quadriceps muscle to assess the expression of myokines (IL-10, IL-1ra and IL-6) (by immunohistochemistry and image analyses). The BR (smooth muscle, epithelium, collagen and elastic fibers deposition, and mucus production) was also evaluated by image analysis. Results: It was not observed any production of myokines (p>0.05). The levels of IgE and IgG1, cell migration, production of inflammatory mediators, and the BR were increased in the OVA groups (p<0.05); that still showed a decreased production of the GR (p<0.05). The AT promoted an increase of GR in the airway smooth muscle from the 3rd day, the production of IL-10 and IL- 1ra were increased from day 7 for cells peribronchial, while NF-kB, IL-4, IL-5, eotaxin, RANTES, ICAM-1, VCAM-1, VEGF, eosinophil counting in BALF were reduced, and reversed the smooth muscle thickening, epithelium and deposition of collagen fibers too (p<0.05). Interestingly, the decreasing of TGF-b occurred in the 3rd day, and OPN, elastic fibers, mucus occurred after 15 days of AT, while IgE and IgG1, and neutrophils were reduced only after 30 days (p<0.05). Conclusion: The anti-inflammatory mechanism by increasing the GR on the smooth muscle of the airways was initiated from the 3rd day of the AT, followed by an increase of IL-10 and IL-1ra and a reduction of NF-kB from the 7th day of the AT, reversed the effects of chronic allergic inflammation and bronchial remodeling

Indiana University-Purdue University Indianapolis (IUPUI) / Neurofibromatosis Type 1 (NF1) is a genetic disorder resulting from mutations in the NF1 tumor suppressor gene. Neurofibromin is the protein product of NF1 and functions as a negative regulator of Ras activity in both hematopoietic and vascular wall cells, which are critical for maintaining blood vessel homeostasis. NF1 patients are predisposed to chronic inflammation and premature cardiovascular disease, including development of large arterial aneurysms, which may result in sudden death secondary to their rupture. However, the molecular pathogenesis of NF1 aneurysm formation is completely unknown. Utilizing a novel model of Nf1 murine aneurysm formation, we demonstrate that heterozygous inactivation of Nf1 (Nf1+/-) results in enhanced aneurysm formation with myeloid cell infiltration and increased reactive oxygen species in the vessel wall. Using cell lineage-restricted transgenic mice, we show that loss of a single Nf1 allele in myeloid cells is sufficient to recapitulate the Nf1+/- aneurysm phenotype in vivo. Additionally, oral administration of simvastatin, a statin with antioxidant and anti-inflammatory effects, significantly reduced aneurysm formation in Nf1+/- mice. Finally, the antioxidant apocynin was administered orally and also resulted in a significant reduction of Nf1+/- aneurysms. These data provide genetic and pharmacologic evidence that neurofibromin-deficient myeloid cells are the central cellular triggers for aneurysm formation in a novel model of NF1 vascular disease, implicated oxidative stress as the key biochemical mechanisms of NF1 aneurysm formation and provide a potential therapeutic target for NF1 vasculopathy.

Indiana University-Purdue University Indianapolis (IUPUI) / Chronic inflammatory disorders are characterized by an increase in excitability of small diameter sensory neurons located in dorsal root ganglia (DRGs). This sensitization of neurons is a mechanism for chronic inflammatory pain and available therapies have poor efficacy and severe adverse effects when used chronically. Prostaglandin E₂ (PGE₂) is an inflammatory mediator that plays an important role in sensitization by activating G-protein coupled receptors (GPCRs) known as E-series prostaglandin receptors (EPs) coupled to the protein kinase A (PKA) pathway. EPs are known to downregulate upon prolonged exposure to PGE₂ or in chronic inflammation, however, sensitization persists and the mechanism for this is unknown. I hypothesized that persistence of PGE₂-induced hypersensitivity is associated with a switch in signaling caused by prolonged exposure to PGE₂ or the neurotrophin nerve growth factor (NGF), also a crucial inflammatory mediator. DRG cultures grown in the presence or absence of either PGE₂ or NGF were used to study whether re-exposure to the eicosanoid is able to cause sensitization and activate PKA. When cultures were grown in the presence of NGF, PGE₂-induced sensitization was not attenuated by inhibitors of PKA. Activation of PKA by PGE₂ was similar in DRG cultures grown in the presence or absence of NGF when phosphatase inhibitors were added to the lysis and assay buffers, but significantly less in cultures grown in the presence of NGF when phosphatase inhibitors were not added. In DRG cultures exposed to PGE₂ for 12 hours-5 days, sensitization after re-exposure to PGE₂ is maintained and resistant to PKA inhibition. Prolonged exposure to the eicosanoid caused complete loss of PKA activation after PGE₂ re-exposure. This desensitization was homologous, time dependent, reversible, and insurmountable by a higher concentration of PGE₂. Desensitization was attenuated by reduction of expression of G-protein receptor kinase 2 and was not mediated by PKA or protein kinase C. The presented work provides evidence for persistence of sensitization by PGE₂ as well as switch from the signaling pathway mediating this sensitization after long-term exposure to NFG or PGE₂.

No / Osteoarthritis is an inflammatory disease of load-bearing synovial joints that is currently treated with drugs that exhibit numerous side effects and are only temporarily effective on pain, the main symptom of the disease. Consequently, there is an acute need for novel, safe and more effective chemotherapeutic agents for the treatment of osteoarthritis and related arthritic diseases. Resveratrol is a phytoalexin stilbene produced naturally by plants including red grapes, peanuts and various berries. Recent research in various cell models has demonstrated that resveratrol is safe and has potent anti-inflammatory properties. However, its potential for treating arthritic conditions has not been explored. In this study we provide experimental evidence that resveratrol inhibits the expression of VEGF, MMP-3, MMP-9 and COX-2 in human articular chondrocytes stimulated with the pro-inflammatory cytokine IL-1beta. Since these gene products are regulated by the transcription factor NF-kappaB, we investigated the effects of resveratrol on IL-1beta-induced NF-kappaB signaling pathway. Resveratrol, like N-Ac-Leu-Leu-norleucinal (ALLN) suppressed IL-1beta-induced proteasome function and the degradation of IkappaBalpha (an inhibitor of NF-kappaB) without affecting IkappaBalpha kinase activation, IkappaBalpha-phosphorylation or IkappaBalpha-ubiquitination which suppressed nuclear translocation of the p65 subunit of NF-kappaB and its phosphorylation. Furthermore, we observed that resveratrol as well as ALLN inhibited IL-1beta-induced apoptosis, caspase-3 activation and PARP cleavage in human articular chondrocytes. In summary, our results suggest that resveratrol suppresses apoptosis and inflammatory signaling through its actions on the NF-kappaB pathway in human chondrocytes. We propose that resveratrol should be explored further for the prophylactic treatment of osteoarthritis in humans and companion animals.